Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a nationwide review unlock the secrets of a rare adrenal cancer?

NCT ID NCT06279442

Knowledge-focused Sponsor: Latin American Cooperative Oncology Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This study looks back at the medical records of 150 adults in Brazil diagnosed with adrenocortical carcinoma, a rare cancer of the adrenal glands. Researchers will collect details on age, gender, location, tumor stage, hormone activity, and treatments received since the year 2000. The goal is to build a detailed picture of who gets this cancer and how it behaves in the Brazilian population. This information may help doctors recognize the disease earlier and tailor care more effectively.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If this study succeeds, it could provide a clearer picture of how adrenocortical carcinoma affects people in Brazil, potentially guiding earlier detection and better treatment strategies.
What could go wrong
This is an observational study, so it cannot test new treatments. The data comes from medical records, which may be incomplete or inconsistent across sites.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

150 people

The number who actually took part.

Started

Oct 2024

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Data will be included from 150 participants diagnosed with adrenocortical carcinoma who meet the study's inclusion and exclusion criteria. Data will be collected from the medical records of the included research sites throughout Brazil.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants over 18 years old; * Diagnosis of adrenocortical carcinoma with at least one clinical evaluation at the reference institution; * Initial diagnosis or recurrence from the year 2000 onwards. Exclusion Criteria: * Participants with insufficient clinical or pathological data in the medical records.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma adrenal are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenal carcinoma adrenal cortex carcinoma adrenal cortex neoplasm carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma adrenal Carcinoma, adrenocortical recurrent

Contacts and locations

Locations

  • A.C. Camargo Cancer Center

    São Paulo, São Paulo, 01.509-001, Brazil

  • BP - A Beneficência Portuguesa de São Paulo

    São Paulo, São Paulo, 01.323-030, Brazil

  • FUNFARME - Hospital de Base de São José do Rio Preto

    São José do Rio Preto, São Paulo, 15.090-000, Brazil

  • HAOC - Hospital Alemão Oswaldo Cruz

    São Paulo, São Paulo, 01.327-001, Brazil

  • HUJBB - Hospital Universitário João de Barros Barreto da UFPA

    Belém, Pará, 66073-000, Brazil

  • Hospital Erasto Gaertner

    Curitiba, Paraná, 81.520-060, Brazil

  • Hospital Santa Joana Recife (Instituto Américas PE)

    Recife, Pernambuco, 52.011-000, Brazil

  • Hospital de Amor de Barretos

    Barretos, São Paulo, 14784-400, Brazil

  • Hospital do Câncer do Maranhão Dr. Tarquínio Lopes Filho

    São Luís, Maranhão, 65.015-460, Brazil

  • INCA - Instituto Nacional de Câncer

    Rio de Janeiro, Rio de Janeiro, 20.230-130, Brazil

  • Pronutrir - Suporte Nutricional e Quimioterapia

    Fortaleza, Ceará, 60.810-180, Brazil

  • UOPECCAN - Hospital do Câncer de Cascavel

    Cascavel, Santa Catarina, 85.806-300, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.